A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
Coherus Oncology, Inc.
IGM Biosciences, Inc.
Memorial Sloan Kettering Cancer Center
Taiho Pharmaceutical Co., Ltd.
OHSU Knight Cancer Institute
GSO Global Clinical Research BV
Eli Lilly and Company
mAbxience Research S.L.
UNC Lineberger Comprehensive Cancer Center
Sanofi
M.D. Anderson Cancer Center
University of Pittsburgh
H. Lee Moffitt Cancer Center and Research Institute
Merck KGaA, Darmstadt, Germany
Memorial Sloan Kettering Cancer Center